Arterra Bioscience (ARBS) Q2 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 TU earnings summary
14 Jul, 2026Executive summary
Specializes in green biotech R&D, focusing on sustainable products and enabling technologies for cosmetics, agriculture, and nutraceuticals.
Listed on Euronext Growth Milan since October 2019, with a history of collaborations with leading industry players and research institutions.
Significant events and developments
Maintains a long-term research contract with Intercos S.p.A., a global leader in cosmetics, since 2008.
Launched Vitalab joint venture with Intercos in 2010, targeting innovative skincare and functional makeup products.
Ongoing collaboration with Isagro SpA in the agrochemical sector.
Market and industry conditions
Operates in multiple industrial sectors, leveraging biotechnological advances for sustainable solutions.
Engages in partnerships with companies, universities, and research institutes in Italy and internationally.
Latest events from Arterra Bioscience
- Net profit more than doubled on 41% revenue growth, driven by strong cosmetic raw material sales.ARBS
H1 20247 May 2026 - Net profit more than doubled to €1.09M as production value and EBITDA surged.ARBS
H1 20257 May 2026 - Revenue up 43% in 1H 2024, led by strong cosmetic raw material sales growth.ARBS
Q2 2024 TU7 May 2026 - Revenue up 7% year-over-year to €2.8 million, with strong growth in cosmetic raw materials.ARBS
Q3 2024 TU7 May 2026 - Revenue up 28.21% to €4.2M, driven by strong cosmetic raw materials sales growth.ARBS
Q4 2024 TU7 May 2026 - Q1 2025 revenue rose 21.6% year-over-year to €1.3 million, led by cosmetic raw material sales.ARBS
Q1 2025 TU7 May 2026 - Revenue up 12.8% year-over-year to €2.6M, led by strong cosmetic raw material sales growth.ARBS
Q2 2025 TU7 May 2026 - Revenue up 29% year-over-year to €3.6M, with strong growth in cosmetic raw materials sales.ARBS
Q3 2025 TU7 May 2026 - Revenue up 11.42% to €4.6M, led by strong cosmetic raw material sales growth.ARBS
Q4 2025 TU7 May 2026